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a b s t r a c t 
Background: In late 2012, ivacaftor became available in the UK for people with cystic fibrosis (CF) aged 
6 years and over with a G551D mutation. Long-term changes in treatment patterns have not previously 
been reported. We investigated long-term treatment patterns in people with CF with a G551D mutation 
who took ivacaftor and compared these with non-ivacaftor-treated cohorts using the UK Cystic Fibrosis 
Registry. 
Methods: Using 2007-2018 data we compared treatment patterns between four cohorts: 1: ivacaftor- 
treated; 2: ivacaftor era (2013-2018), ineligible genotype (no G551D mutation); 3: pre-ivacaftor era (2007- 
2012), eligible genotype (G551D mutation); 4: pre-ivacaftor era, ineligible genotype. Treatments included: 
inhaled antibiotics, dornase alfa, hypertonic saline, chronic oral antibiotics and supplementary feeding. 
Results: Up to 2012 the percentages of people taking each treatment were similar between the two 
cohorts defined by genotype and tended to increase by year with a similar slope. Once ivacaftor was 
introduced, the use of other treatments tended to decrease or remain stable by year for the ivacaftor- 
treated cohort, whereas it remained stable or increased in the non-ivacaftor-treated cohort. This led to 
differences in treatment use between the two cohorts in the ivacaftor-era, which became more marked 
over time. 
Conclusions: We have shown a clear divergence in treatment patterns since the introduction of ivacaftor 
in a number of key treatments widely used in CF. Further research is needed to investigate whether the 
differences in treatment patterns are associated with changes in health outcomes. 



























Ivacaftor was the first CF transmembrane conductance regula- 
or (CFTR) modulator therapy to be licensed for the treatment of 
eople with cystic fibrosis (CF) with specific CF-causing genetic 
utations. Phase III randomized controlled trials have found evi- 
ence that treatment with ivacaftor is associated with significant 
mprovement in clinical outcomes including FEV 1 for individuals 
ith a Gly551Asp-CFTR (G551D) mutation [ 1 , 2 ]. Ivacaftor has been 
rescribed as standard care in the UK to people with CF aged 6 
ears and over with a G551D mutation since 2013, with access 
ater expanded to individuals with eight other gating mutations, ∗ Corresponding author at: Emily Granger, Department of Medical Statistics, Fac- 
lty of Epidemiology and Population Health, London School of Hygiene and Tropical 
edicine, Keppel St, Bloomsbury, London WC1E 7HT, United Kingdom. 
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since the introduction of ivacaftor? Journal of Cystic Fibrosis, https://doged six months and older, and with an Arg117His-CFTR mutation. 
ecent studies of the effect of ivacaftor in the eligible CF popu- 
ation have been undertaken using registry data from the UK and 
S, and have found that treatment with ivacaftor is associated with 
mproved outcomes including better preserved lung function, im- 
roved nutritional status and decreased risk of hospitalisations [3- 
] . 
Treatment burden is an important factor in the quality of life of 
eople with CF and identifying ways to reduce treatment burden 
s a top research priority for the CF community [ 7 , 8 ]. The effect of
vacaftor use on patient reported outcomes was studied in a ran- 
omized controlled trial using the Cystic Fibrosis Questionnaire- 
evised (CFQ-R) by Quittner et al. [9] , who found evidence of re- 
uced treatment burden in the ivacaftor-treated group, though this 
id not capture the nature of any reduction in the treatment bur- 
en. Reasons may include changes in perception of ‘burden’ fol- 
owing introduction of modulators, or withdrawal of treatments . 
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ollowing modulator introduction. To our knowledge, long-term 
hanges in treatment patterns in ivacaftor-treated patients have 
ot been reported to date. Volkova et al. reported prevalence of 
reatments such as dornase alfa, hypertonic saline and chronic an- 
ibiotics at the time of initiating ivacaftor in the UK and US patient 
egistries, but not at follow-up [6] . Hubert et al. reported findings 
rom a retrospective French multi-centre study 1-2 years after ini- 
iating ivacaftor, including an observation that the proportion of 
atients taking chronic therapies such as nebulised dornase alfa 
ecreased over this period [10] . 
We hypothesised that the introduction of ivacaftor would lead 
o changes in the long-term use of other key treatments in CF and 
imed to investigate this in a large observational dataset. In this 
tudy we use UK CF Registry data to describe treatment use up 
o 6 years after initiating ivacaftor in individuals with a G551D 
utation. The documentation of all chronic treatments in the reg- 
stry permits an opportunity to evaluate these in detail. Treatments 
onsidered are inhaled antibiotics, chronic oral antibiotics, dornase 
lfa, hypertonic saline and supplementary feeding. To appropri- 
tely investigate associations between ivacaftor and other long- 
erm treatment use, methodology should also take account tem- 
oral changes in treatment use in the wider CF population. We 
herefore compare treatment patterns in ivacaftor-treated individ- 
als with patterns in individuals in the same time period but not 
eceiving ivacaftor due to their genotype. We also compare treat- 
ent patterns over time in similar cohorts defined by genotype, 
ut observed in the time period before ivacaftor became avail- 
ble. The clinical characteristics of the cohort defined by genotype 
nd time period are summarised, and we investigate whether any 
ifferences in treatment patterns between groups differs between 
EV 1 %, age, and sex. 
. Methods 
.1. Data source 
We used data from the UK Cystic Fibrosis Registry, a national 
atabase sponsored and managed by the Cystic Fibrosis Trust. The 
egistry was established in 1995 and records demographic data and 
nnual review data on clinical measurements and treatment use, 
n nearly all people with CF in the UK [11] . National Health Ser-
ice (NHS) Research Ethics approval has been granted for data col- 
ection into the registry and each patient, or their parent/guardian, 
rovides written consent. 
Ivacaftor was introduced in the UK in 2013. For this study we 
sed registry data from 2007-2018, giving six years before ivacaftor 
as introduced (pre-ivacaftor era: 2007-2012) and six years af- 
er (ivacaftor era: 2013-2018) to compare longitudinal patterns of 
reatment use in the pre-ivacaftor and ivacaftor eras. The following 
reatments were considered: inhaled antibiotics, chronic oral an- 
ibiotics, dornase alfa, hypertonic saline and supplementary feed- 
ng. For chronic oral antibiotics we considered all types combined, 
nd also azithromycin and flucloxacillin separately due to the dif- 
erent clinical indications for these being prescribed for long-term 
se. Supplementary feeding was considered separately according to 
hether it was oral or by gastrostomy. Use of ivacaftor and each 
ther treatment (yes/no) over the past year is available for each 
nnual review recorded in the registry. Dates of starting and stop- 
ing ivacaftor were also available and were used to verify ivacaftor 
se for all individuals and identify individuals who stopped iva- 
aftor during the follow-up period. 
We also used registry data on genotype, age, sex, FEV 1 % pre- 
icted (recorded at each annual review, measured using the GLI 
quations [12] ), and number of days intravenous (IV) antibiotic use 
ver the past year (recorded at each annual review). 2 .2. Statistical analysis 
We investigated patterns of treatment use over the 6 years in 
he two eras (2007-2012, 2013-2018) both in ivacaftor-treated indi- 
iduals (who started using ivacaftor in the ivacaftor era) and in in- 
ividuals who were not eligible for ivacaftor due to their genotype. 
his enables an investigation of whether any changes in treatment 
atterns seen in the ivacaftor users in the ivacaftor era could be 
ue in part to general changes over time in treatment use. 
Ivacaftor was first licenced in the UK for people aged 6 and 
lder with a G551D mutation in late 2012 (England) and 2013 
Scotland, Northern Ireland), and later licenced for individuals with 
ther gating mutations (2015) or the R117H mutation (2018), and 
ounger patients. We focus on individuals with a G551D muta- 
ion who began taking ivacaftor in 2012 or 2013; these patients 
orm the ‘ivacaftor-treated’ cohort, and the majority (92.2%) initi- 
ted ivacaftor in 2013. We did not include people who started iva- 
aftor in later years because we are interested in patterns of other 
reatments as a function of the time since starting ivacaftor. For 
his study an ‘eligible genotype’ was defined as having at least one 
551D mutation. 
We defined four cohorts of individuals: ivacaftor-treated (2013- 
018) (IVA-ELIG); ivacaftor era (2013-2018), ineligible genotype 
IVA-INELIG); pre-ivacaftor era (2007-2012), eligible genotype 
PRE-IVA-ELIG); pre-ivacaftor era (2007-2012), ineligible genotype 
PRE-IVA-INELIG). 
The ‘baseline year’ was defined as the year 2013 for cohorts 
VA-ELIG and IVA-INELIG (ivacaftor era), and 2007 for cohorts PRE- 
VA-ELIG and PRE-IVA-INELIG (pre-ivacaftor era). For all cohorts, 
e excluded children who were under 6 years old at baseline 
nd people who received a transplant (from the year in which 
he transplant was recorded onwards). We excluded people from 
VA-ELIG if they stopped treatment with ivacaftor (from the year 
hey stopped onwards) and from IVA-INELIG if they started iva- 
aftor during a later year (from the year ivacaftor treatment initi- 
ted onwards), when it became available for individuals with non- 
551D mutations. Many individuals appear in both IVA-ELIG and 
RE-IVA-ELIG or in IVA-INELIG and PRE-IVA-INELIG as they have 
ata recorded in the registry in both time periods. 
There is some missing data on use of chronic treatments and 
e used a pragmatic imputation approach to address this. Where 
 missing value appeared in a year between two non-missing val- 
es that were the same, we set the missing value to be the same as
he two non-missing values. For example, if a person was missing 
ata on use of a given treatment in 2014, but was recorded as tak- 
ng this treatment in 2013 and 2015, we assumed they were also 
aking it in 2014. After this procedure, observations with remain- 
ng missing data were excluded for the year the data were missing. 
o assess the sensitivity of results to this imputation method, we 
epeated the analyses twice using different methods: all missing 
ata were imputed as either 0 (indicating no treatment use) or 1 
indicating treatment use). 
We summarised key characteristics of individuals in the four 
ohorts by year (age, FEV 1 % and annual number of days on in- 
ravenous therapy (IV) (including hospital admissions and home 
ourses)). For each cohort, we calculated the proportions of peo- 
le taking each of the treatments of interest by year, and corre- 
ponding 95% confidence intervals. Results are presented graphi- 
ally to illustrate changes in treatment use over time in the four 
roups. The analysis looking at proportions of users over time 
as repeated separately in males and females, in children and 
dults (using age at baseline year), and by FEV 1 % in the base- 
ine year (FEV 1 % ≤60, 60 < FEV 1 % ≤80, FEV 1 % > 80). Chi-squared tests
ere used to test for differences in treatment use in the eligible 
nd ineligible genotype groups in the baseline year and in the fi- 
al year in the pre-ivacaftor era and the ivacaftor era. Hypothesis 
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) ests were not conducted for all years to avoid issues with multiple 
esting. We also investigated whether the trend in the proportions 
f treatment use over time differs by genotype group, in the pre- 
vacaftor era and the ivacaftor era, separately. This analysis used a 
roup-level logistic regression of the proportions of treatment use 
n genotype group, time, and their interaction. A test of the null 
ypothesis that the interaction term is equal to zero corresponds 
o a test of whether there is a difference in the trend of propor-
ions over time by genotype group. All analyses were conducted in 
 version 3.6.1. 
. Results 
Table 1 presents the number of people in each cohort by year, 
long with descriptive statistics. Among those with the eligible 
enotype, there were 402 individuals in the ivacaftor-treated co- 
ort (IVA-ELIG)) and 287 in the pre-ivacaftor era (PRE-IVA-ELIG) in 
he baseline year. Among those with an ineligible genotype, there 
ere 6588 individuals in the ivacaftor era (IVA-INELIG) and 3874 
n the post-ivacaftor era (PRE-IVA-INELIG) in the baseline year. The 
umbers in each cohort may increase by year, if new people enter 
he registry who meet the inclusion criteria, or decrease, if exist- 
ng people are excluded or lost to follow-up. A flowchart showing 
atient selection for each cohort by year is provided in the sup- 
lementary material (Supplementary Figure 1). The total numbers 
f people in cohorts IVA-ELIG, IVA-INELIG, PRE-IVA-ELIG and PRE- 
VA-INELIG at any time point were 416, 7347, 429 and 6236, re- 
pectively. There is no entry to the ivacaftor-treated cohort after 
he baseline year, whereas individuals can enter as well as exit the 
ther three cohorts. The analyses were repeated restricting to in- 
ividuals observed in the baseline year and results were similar to 
hose reported here. 
Average ages for the four cohorts ranged between 20.3 and 22.9 
t baseline and increase by year. The average FEV 1 % at baseline 
as highest in the ivacaftor-treated cohort at 73.8 (measured in 
he first year that they started ivacaftor). This increased to 75.6 in 
015 and back down to 73.3 in 2018. For the remaining cohorts, 
he average FEV 1 % tended to decrease over time. The proportions 
f people in each category of total IV days were similar across co- 
orts in the baseline year, but trends over time differed. For exam- 
le, the proportion of people with zero IV days increased over time 
n the ivacaftor-treated cohort, but decreased for the other three 
ohorts. The proportions with pancreatic insufficiency at baseline 
anged between 86.6% (IVA-INELIG) and 91.2% (IVA-ELIG). In the 
vacaftor-era, there were consistently higher proportions of people 
ith pancreatic insufficiency in the ivacaftor-treated cohort, com- 
ared to the ineligible cohort. 
Figure 1 presents the proportions (and 95% confidence inter- 
als) in each cohort prescribed different treatments by year. Cor- 
esponding numerical results are shown in Supplementary Table 
. For all treatments, in the pre-ivacaftor era, the proportions are 
imilar between the two genotype cohorts in 2007 and tend to in- 
rease similarly in both cohorts until 2012. For example, in 2007 
5% (95% CI: 40-51%) of the eligible genotype group and 52% (50- 
4%) of the ineligible genotype group used inhaled antibiotics, and 
t the end of the pre-ivacaftor era in 2012 65% (60-70%) of the 
ligible genotype group and 66% (64-67%) of the ineligible geno- 
ype group used inhaled antibiotics. Hypothesis tests indicate no 
vidence of differences in treatment use between genotype groups 
n 2007 or 2012, except for inhaled antibiotics in 2007 (p = 0.035) 
nd dornase alfa in 2012 (p = 0.015) (Supplementary Table 1). Af- 
er ivacaftor was introduced, we observe differences in treatment 
atterns in the two genotype groups. For inhaled antibiotics and 
hronic oral antibiotics, treatment use decreases over time for both 
enotype groups in the ivacaftor era, but more so in the ivacaftor- 
reated cohort. For example, in 2013 65% of individuals had used 3 
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Fig. 1. The proportions and 95% confidence intervals in each cohort prescribed different treatments by year. 
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nhaled antibiotics in both genotype groups (60-69% for IVA-ELIG 
nd 64-66% for IVA-INELIG), while in 2018 this had decreased to 
0% (35-45%) in the eligible genotype group (ivacaftor users) com- 
ared to 56% (55-58%) in the ineligible genotype group. For dor- 
ase alfa, hypertonic saline solution and azithromycin, treatment 
se continues to increase in the ivacaftor era for the ineligible 
enotype cohort, but decreases for the ivacaftor-treated cohort. 
roportions using supplementary feeding (oral or gastrostomy) are 
enerally much lower across all cohorts (with particularly low pro- 
ortions observed for gastrostomy, hence the y-axis for this sub- 
lot is on a different scale). In the ivacaftor era the proportions us- 
ng supplementary feeding remain approximately flat over time in 
oth genotype cohorts for supplementary feeding, though with the 
roportions being lower in the ivacaftor-treated cohort. Hypothe- 
is tests indicate significant differences in treatment use between 
enotype cohorts in 2018, for all treatments except flucloxacillin 
Supplementary Table 1). Flucloxacillin was the only treatment 
or which treatment patterns were similar between the genotype 
roups across all years. 
Figure 2 presents results separately by FEV 1 % in the baseline 
ear, sex and age. Results are shown for inhaled antibiotics, dor- 
ase alfa and hypertonic saline solution. Further results are given 
n Supplementary Tables 2-8 and Supplementary Figures 2-4. 
In the pre-ivacaftor era treatment use is similar in both geno- 
ype groups across all three FEV 1 % subgroups. For inhaled antibi- 
tics, dornase alfa and hypertonic saline, differences in treatment 
se between the two genotype groups at the end of the ivacaftor 
ra are larger for people with high lung function (FEV 1 % > 80), com-
ared to those with moderate or low lung function. Lower propor- 
ion of patients prescribed dornase alfa and hypertonic saline were 
lso noted in children, with the close correlation between age and 
EV 1 % noted. The subgroup analyses are described further in the 
nline supplementary data. 
We found no evidence of a difference in the trend of propor- 
ions of treatment use over time between the two genotype groups 
n the pre-ivacaftor era (Supplementary Table 9). In the ivacaftor- 
ra, there was a significant difference (at the 5% significance level) 
n the trend of proportions over time between genotype groups, for 
ll treatments except flucloxacillin and oral supplementary feeding 
Supplementary Table 9). 
Results were very similar between different missing data impu- 
ation methods, indicating that the observed trends were not sen- 
itive to how missing data were handled (results not shown). 
. Discussion 
We have shown a clear divergence in treatment use over time 
etween individuals treated with ivacaftor and those untreated due 
o their genotype for a number of long-term treatments widely 
sed in CF, including dornase alfa, hypertonic saline and inhaled 
ntibiotics. When comparing treatment patterns in the two geno- 
ype groups in the time period before the introduction of ivacaftor 
e saw few differences, suggesting that the differences in treat- 
ent use seen in the ivacaftor era are not explained by other dif- 
erences between the two genotype groups. We found evidence 
or treatment differences between ivacaftor-treated and compara- 
or groups for dornase alfa and hypertonic saline within two years 
f ivacaftor initiation. Differences in treatment use between the 
vacaftor-treated and comparator group were most pronounced for 
hildren and for those with high lung function (FEV 1 % > 80). Our 
nalysis represents the first detailed description of treatment pat- 
erns within the UK ivacaftor-treated population with a G551D mu- 
ation following its introduction into routine clinical care. Hubert 
t al. [7] found a decrease in prescribed dornase alfa two years 
fter initiating ivacaftor and this is confirmed in our larger popu- 
ation. 5 We found changes in treatment patterns within the two pre- 
vacaftor era cohorts tended to mirror each other, for example 
n increasing proportion of people on inhaled antibiotics between 
007-2012. The general increasing trend over time may reflect in- 
reasing age, changes in the quality of data capture for chronic 
edications within the Registry or changes in clinical practice over 
ime. 
We conducted a descriptive analysis. As such, we did not ac- 
ount for differences in the age/sex distribution of the different co- 
orts. However, the ivacaftor-treated group was on average older 
han the ineligible genotype group in the ivacaftor era, and the 
eduction in the proportions of individuals using other treatment 
ver time is seen in spite of this. Furthermore, broadly similar pat- 
erns of treatment use were seen when we conditioned on sex, 
ge and FEV 1 %. Our analyses were conducted by cohort rather than 
ithin-person. Further investigations could consider within-person 
reatment patterns. Furthermore, it will be of interest to estimate 
he impact of ivacaftor initiation on cessation of other treatments, 
ith adjustment for confounding. One limitation of our study is 
hat there have been a number of changes to the data capture 
f chronic medications within the UK CF Registry over the past 
ecade, resulting in improved capture of use of chronic treatments 
n the registry. However, our comparison of genotype groups con- 
emporaneously limits the impact of this on the interpretation of 
esults. Further limitations include missing data, possible viola- 
ions of our assumption that data were missing at random, and 
he possibility of inaccuracies in the data, such as misclassification 
f treatment status. 
Understanding the association between ivacaftor use and ongo- 
ng prescription of other chronic treatments is important both from 
 treatment burden perspective and to appropriately inform health 
echnology appraisals. National registries such as the UK CF Reg- 
stry provide the opportunity to track these changes. The registry 
ecords whether a clinical care team includes a particular treat- 
ent for each patient in their list of current treatments (i.e. re- 
ecting prescription), rather than whether the patient has actually 
een taking that treatment on a regular basis or indeed at all. Ad- 
erence levels are unknown and it is possible that the changes 
n treatment patterns over time may in fact be underestimated. 
ower proportions of people prescribed chronic treatments in the 
vacaftor group may reflect treatment discontinuation in response 
o no longer considering a therapy necessary, or recognition by the 
linical team (and therefore removal from a current medication 
ist) that the treatment is not being taken despite a clinical rec- 
mmendation to do so. Treatment burden in CF is high ([ 8 , 13 , 14 ])
nd ways to simplify this burden have been recognised as a prior- 
ty area for clinical trials ([ 7 , 15 ]). The current rationale for discon-
inuing existing chronic treatments for patients on ivacaftor is not 
vidence based and the impact on clinical outcomes unknown. 
The treatment differences we report within this observational 
ata may be important in relation to longer-term clinical out- 
omes. It is of interest to investigate the impact of changes in 
se of other treatments on clinical outcomes in people taking iva- 
aftor, and to extend this when similar data become available from 
atients taking elexacaftor-tezacaftor-ivacaftor. Such investigations 
ill complement the results that will be yielded from current or 
lanned randomised controlled trials SIMPLIFY (ClinicalTrials.gov: 
CT04378153) and CF STORM (EudraCT number 2020-005864-77), 
hich aim to assess treatment simplification for mucoactive neb- 
lised therapies in patients on elexacaftor-tezacaftor-ivacaftor. Un- 
erstanding the association between change in treatment patterns 
nd clinical outcomes is important to help interpret real-world ef- 
ectiveness data on e.g. lung function outcomes of patients on CFTR 
odulators, particularly if there is any deviation from an antici- 
ated degree of efficacy that may have been expected from the 
riginal phase III clinical trials. Multiple factors may contribute 
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Fig. 2. The proportions and 95% confidence intervals in each cohort prescribed inhaled antibiotics, dornase alfa and hypertonic saline solution by year, stratified by FEV 1 % at 
baseline, sex and age. 
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[  o this, but one possible explanation may be that treatment pat- 
erns for existing chronic therapies have not remained static. With 
he opportunity for significant potential benefits of highly effective 
odulators on long-term outcomes in people with CF, it is impor- 
ant that this is evaluated as a priority to help inform patients’ and 
linical care team’s decision making about long-term outcomes. 
In conclusion, we have shown that there are clear differences in 
reatment patterns as documented on the CF Registry over a 5 year 
eriod for those treated with ivacaftor for G551D mutation, com- 
ared to a contemporary cohort not using ivacaftor. The method- 
logy employed to compare groups provides an opportunity to un- 
erstand the association of these changes with longer-term clinical 
utcomes. 
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